Greenwich LifeSciences (NASDAQ:GLSI) traded higher on Wednesday after the immunotherapy developer updated on the commercial manufacturing of its lead candidate GP2, which is currently undergoing a ...

Snehal Patel, the CEO and CFO of $GLSI ($GLSI), bought 2,500 shares of the company on 01-10-2025. This trade was reported by Quiver Quantitative using data from a ...

Greenwich LifeSciences, Inc.'s main program, GLSI-100, faces challenges in proving its benefit over existing HER2-positive breast cancer treatments, with ongoing phase 3 trial results expected by ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Greenwich LifeSciences (GLSI – Research Report) ...

Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A preliminary review of FLAMINGO-01 HLA data in both the HLA-A*02 ...

1 Day GLSI 0.65% DJIA -0.37% Russell 2K 0.00% Health Care/Life Sciences 0.69% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Greenwich LifeSciences reports preliminary HLA data from Phase III trial FLAMINGO-01 evaluating GLSI-100 for preventing breast cancer recurrences. Greenwich LifeSciences, Inc. provided an update ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...